I’ve never met anyone who found this information helpful Written by Lara Govendo “You might live long enough to finish college, maybe even get married, but …” I imagine this is what the textbooks used to say about cystic fibrosis (CF) when I was in college. While I heard such things at medical appointments, I refused to let that narrative define my life. Yet many medical professionals seem to consider this a necessary conversation with patients. Not with this patient , thoug

Study suggests a simple measure could complement lung function testing   Written by Steve Bryson , PhD Handgrip strength was associated with breathing muscle strength in adults with cystic fibrosis (CF), according to a new study, suggesting the simple test may help complement standard lung function tests in clinical care. The research also found that lung function and breathing muscle strength were related to a combination of factors, including handgrip strength, physical ac

Izmir February 13, 2026 — The Middle East Cystic Fibrosis Association (MECFA) has officially launched MADI: The Path to Progress, a three-year regional initiative designed to address one of the most critical barriers facing children with cystic fibrosis (CF) across the Middle East, North Africa, and parts of Central and South Asia: lack of diagnosis. While scientific breakthroughs have transformed cystic fibrosis care in high-income countries, many children in low- and middle

Age, fitness, screen time, and support linked to physical activity Written by Andrea Lobo, PhD | The amount of physical activity children and adolescents with cystic fibrosis (CF) get is linked to their age, physical abilities, screen time, and several other everyday factors, according to a recent study. Other factors tied to physical activity included taking part in organized sports, having social support from others, and even the time of year. “Our findings underscore the

How I've worked to keep hope alive throughout my CF and transplant journey Written by Lara Govendo I’m no stranger to frigid temperatures and dark days, as it often feels like the tundra here in Vermont. As we approach the winter solstice , I’m reflecting on the symbolism of letting the light in after dark times. I was born in the wee hours of Dec. 22, just as we in the northern hemisphere are emerging from the darkest day of the year and tiptoeing toward lighter days. My jo

Phase 1 trial data also indicate prolonged exposure of drug to lungs Written by Steve Bryson, PhD | ETD001,  Enterprise Therapeutics ’ inhaled investigational therapy to improve mucus clearance in people with cystic fibrosis (CF) — regardless of the underlying CF-causing mutation — was well tolerated in healthy individuals at doses higher than those predicted to be therapeutic, a study showed. The now-complete Phase 1 safety study (NCT04926701) also showed the inhaled drug

Ciske, David J. Haavisto, Amy MD Laxova, Anita Rock, Lan ZengMichael MD Farrell, Philip M. MD, PhD Author information From the Department of Pediatrics, University of Wisconsin, Madison, Wisconsin.Received for publication Dec 14, 999; accepted Jul 31, 2000. Reprint requests to (P.M.F.) University of Wisconsin Medical School, Room 1217 Medical Sciences Center, 1300 University Ave, Madison, WI 53706. E-mail: pmfarrel@facstaff.wisc.edu Pediatrics 107(4):p 699-705, April 2001 AB

New findings explain wide variability in therapy's effects among CF patients by Marisa Wexler, MS People with cystic fibrosis  (CF) who have certain lung structure abnormalities — ones visible on CT scans — are more likely than those with other issues also seen via imaging to experience improvements in lung function after starting treatment with  Trikafta . That’s according to the results of a new analysis that used imaging scans and artificial intelligence (AI) tools to asse

Adults not eligible for approved therapy report conflicting emotions by Steve Bryson, PhD | Adults with cystic fibrosis  (CF) who are not eligible for Kaftrio  therapy reported feeling forgotten in both the media and research, with conflicting emotions about those who do benefit from the approved treatment, according to a new interview-based study by researchers in the U.K. Study participants noted that they also felt a loss of hope when they realized they weren’t eligible f

Written by RTTNews.com for RTTNews (RTTNews) - BiomX Inc. (PHGE), a clinical stage biopharmaceutical company, announced that an independent Data Monitoring Committee has completed a safety review of adverse events reported in its Phase 2b trial of BX004 in cystic fibrosis. The independent Data Monitoring Committee has recommended that the study continue with revised dosing. Accordingly, the study protocol will be updated, and topline results are now expected in Q2 2026. BX00